OneBac 2.0: Sf9 Cell Lines for Production of AAV1, AAV2, and AAV8 Vectors with Minimal Encapsidation of Foreign DNA

Human Gene Therapy Methods

Volumn 28, Issue 1, 2017, Pages 15-22

  Mietzsch, Mario ^a,b   Hering, Henrik ^a   Hammer, Eva Maria ^a   Agbandje Mckenna, Mavis ^b   Zolotukhin, Sergei ^b   Heilbronn, Regine ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

AAV; baculovirus; OneBac; packaging; Rep binding element (RBE)

Indexed keywords

ADENOVIRUS VECTOR; DNA; PROTEIN VP1;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA SPLICING; GENETIC TRANSDUCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTYPE; SF9 CELL LINE; VIROGENESIS; VIRUS CAPSID; VIRUS INFECTIVITY; VIRUS PURIFICATION; BACULOVIRIDAE; BIOSYNTHESIS; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HELA CELL LINE; HUMAN; THERAPEUTIC USE;

BACULOVIRIDAE; CAPSID; DEPENDOVIRUS; DNA; GENETIC THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; TRANSFECTION;

EID: 85012977484     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2016.164     Document Type: Article

References (23)

1. Scott LJ. Alipogene tiparvovec: A review of its use in adults with familial lipoprotein lipase deficiency. Drugs 2015;75:175-182.
2. Nathwani AC, Reiss UM, Tuddenham EG, et al. Longterm safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014;371:1994-2004.
3. Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-Associated virus in patients with Leber congenital amaurosis type 2. Ophthalmology 2013;120:1283-1291.
4. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012;4:120ra115.
5. Grimm D, Kay MA, Kleinschmidt JA. Helper virusfree, optically controllable, and two-plasmid-based production of adeno-Associated virus vectors of serotypes 1 to 6. Mol Ther 2003;7:839-850.
6. Xiao X, Li J, Samulski RJ. Production of high-Titer recombinant adeno-Associated virus vectors in the absence of helper adenovirus. J Virol 1998;72:2224-2232.
7. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-Associated virus type 2 vectors. Hum Gene Ther 2002;13:1935-1943.
8. Smith RH, Levy JR, Kotin RM. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields hightiter rAAV stocks from insect cells. Mol Ther 2009;17:1888-1896.
9. Aslanidi G, Lamb K, Zolotukhin S. An inducible system for highly efficient production of recombinant adeno-Associated virus (rAAV) vectors in insect Sf9 cells. Proc Natl Acad Sci U S A 2009;106:5059-5064.
10. Mietzsch M, Grasse S, Zurawski C, et al. OneBac: platform for scalable and high-Titer production of adeno-Associated virus serotype 1-12 vectors for gene therapy. Hum Gene Ther 2014;25:212-222.
11. Mietzsch M, Casteleyn V, Weger S, et al. OneBac 2.0: Sf9 cell lines for production of AAV5 vectors with enhanced infectivity and minimal encapsidation of foreign DNA. Hum Gene Ther 2015;26: 688-697.
12. Chen H. Intron splicing-mediated expression of AAV Rep and Cap genes and production of AAV vectors in insect cells. Mol Ther 2008;16:924-930.
13. Mietzsch M, Broecker F, Reinhardt A, et al. Differential adeno-Associated virus serotype-specific interaction patterns with synthetic heparins and other glycans. J Virol 2014;88:2991-3003.
14. Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A 2010;107:10220-10225.
15. Girod A, Wobus CE, Zadori Z, et al. The VP1 capsid protein of adeno-Associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol 2002;83:973-978.
16. Nonnenmacher M, Weber T. Intracellular transport of recombinant adeno-Associated virus vectors. Gene Ther 2012;19:649-658.
17. Becerra SP, Koczot F, Fabisch P, et al. Synthesis of adeno-Associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. J Virol 1988;62:2745-2754.
18. Kohlbrenner E, Aslanidi G, Nash K, et al. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol Ther 2005;12:1217-1225.
19. Hauck B, Murphy SL, Smith PH, et al. Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. Mol Ther 2009;17:144-152.
20. Martin J, Frederick A, Luo Y, et al. Generation and characterization of adeno-Associated virus producer cell lines for research and preclinical vector production. Hum Gene Ther Methods 2013;24:253-269.
21. Lecomte E, Tournaire B, Cogne B, et al. Advanced characterization of DNA molecules in rAAV vector preparations by single-stranded virus next-generation sequencing. Mol Ther Nucleic Acids 2015;4:e260.
22. Hüser D, Weger S, Heilbronn R. Packaging of human chromosome 19-specific adeno-Associated virus (AAV) integration sites in AAV virions during AAV wild-Type and recombinant AAV vector production. J Virol 2003;77:4881-4887.
23. Kakumani PK, Malhotra P, Mukherjee SK, et al. A draft genome assembly of the army worm, Spodoptera frugiperda. Genomics 2014;104:134-143.